Assessment of Potential Interactions Between GBR 12909 and Cocaine - 1
Phase 1
- Conditions
- Cocaine-Related Disorders
- Registration Number
- NCT00100113
- Lead Sponsor
- National Institute on Drug Abuse (NIDA)
- Brief Summary
The purpose of this study is to assess potential interactions between intravenous (IV) cocaine and 3 doses of GBR 12909.
- Detailed Description
This is Phase 1, double-blind, placebo-controlled human laboratory clinical pharmacology study that will assess the potential interactions between IV cocaine and 3 escalating oral doses of GBR 12909. The primary objective is to determine safety of GBR 12909 administration and if there are significant interactions between GBR 12909 treatment concurrent with IV cocaine infusions.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
- Must be within 20% ideal body weight and must weigh at least 45 kg.
- Must understand the study procedures and provide written informed consent.
- Must meet DSM-4 criteria and are non-treatment seeking at time of study.
Exclusion Criteria
- Please contact study site for more information
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Heart rate
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
U of Texas Medical Branch Galveston
🇺🇸Galveston, Texas, United States